Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €99.24 EUR
Change Today -0.62 / -0.63%
Volume 2.0
BM8 On Other Exchanges
As of 5:26 AM 10/5/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BM8) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/20/15 - €140.53
52 Week Low
10/15/14 - €51.45
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

biomarin pharmaceutical inc (BM8) Details

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert Myasthenic Syndrome, an autoimmune disease. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including drisapersen, an exon-51 skipping compound for the treatment of Duchenne muscular dystrophy (DMD); pegvaliase, an enzyme substitution therapy for the treatment of PKU; reveglucosidase alfa, an enzyme replacement therapy for Pompe disease; talazoparib, an orally available poly-ADP ribose polymerase inhibitor for cancer treatment; BMN 111, a peptide therapeutic for achondroplasia treatment; BMN 044, BMN 045, and BMN 053 for DMD treatment; and cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis. In addition, it develops preclinical product candidates for genetic and other metabolic diseases, such as BMN 270 and BMN 250. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. S.A. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono. The company was founded in 1996 and is headquartered in San Rafael, California.

1,681 Employees
Last Reported Date: 03/2/15
Founded in 1996

biomarin pharmaceutical inc (BM8) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $916.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $480.6K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $528.2K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $417.7K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

biomarin pharmaceutical inc (BM8) Key Developments

BioMarin Pharmaceutical Inc. - Special Call

To discuss the acquisition of the global PKU franchise from Merck Serono by BioMarin

Merck KGaA Agrees to Return Kuvan® Rights to BioMarin Pharmaceutical to Strengthen Focus on Core Business

Merck KGaA announced that it has reached an agreement with BioMarin Pharmaceutical Inc. to return the rights to Kuvan®, used to treat phenylketonuria (PKU), a rare metabolism disorder, as the company focuses its healthcare business on core areas. In addition to Kuvan®, the two companies agreed that Merck KGaA, Darmstadt, Germany, will return its option to develop and commercialize Peg-Pal, an investigational drug that is also designed for the treatment of PKU, an autosomal recessive genetic disorder caused by either a defect or a deficiency of the enzyme phenylalanine hydroxylase or its co-factor tetrahydrobiopterin. Merck KGaA will receive an upfront payment of €340 million, equal to five times its annual sales, for Kuvan®, plus up to €185 million in additional milestones for both products. The agreement is expected to become effective January 1, 2016.

Parent Project Muscular Dystrophy Launches Next Phase of Genetic Testing Program, Decode Duchenne in Collaboration with BioMarin Pharmaceutical Inc., PTC Therapeutics, and Sarepta Therapeutics

Parent Project Muscular Dystrophy (PPMD) announced a collaboration with BioMarin Pharmaceutical Inc., PTC Therapeutics, and Sarepta Therapeutics, Inc. in the next phase of the highly successful Decode Duchenne program. Decode Duchenne is a nationwide program to assist individuals with Duchenne muscular dystrophy [2] in accessing genetic testing, interpretation, and counseling. Due to the collaboration and generous support of these partners, Decode Duchenne will provide genetic testing, interpretation, and counseling at no cost to eligible patients who are unable to access testing due to barriers such as a lack of insurance or insufficient insurance coverage. For patients with Duchenne, genetic testing is used to identify the genetic mutation and confirm the diagnosis. In addition, genetic testing can be used not only to determine a patient's eligibility for certain clinical trials, but also their compatibility for potential therapies on the horizon. Despite the benefits of testing, in some cases patients are unable to access genetic testing through their insurance provider. The program will be administered by PPMD through DuchenneConnect [3], a clinical registry that connects people living with Duchenne to clinical trials. To participate in Decode Duchenne, patients must: Have a confirmed diagnosis or be suspected of having Duchenne or Becker muscular dystrophy based on clinical symptoms, as assessed by their treating physician, and have a positive creatine kinase (CK) test; Have not previously had genetic testing, or must require additional genetic testing to identify a causative mutation; Provide documentation to confirm the patient's lack of insurance coverage, insufficient insurance coverage, or a denial of coverage for genetic testing; Be citizens or legal residents of the United States or Canada; The next phase of Decode Duchenne is expected to launch in October 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BM8:GR €99.24 EUR -0.62

BM8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $60.48 USD +0.97
Incyte Corp $126.46 USD +8.53
Jazz Pharmaceuticals PLC $137.50 USD +5.05
Momenta Pharmaceuticals Inc $16.83 USD +0.67
Vertex Pharmaceuticals Inc $115.18 USD +7.95
View Industry Companies

Industry Analysis


Industry Average

Valuation BM8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.0x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at